Mandrola’s Top 10 Cardiology Stories of 2019
It’s probably no surprise that ISCHEMIA and the EXCEL controversy make John Mandrola’s annual list for 2019. He also found good news in heart failure and has words of caution for TAVR expansion.
Related Articles
Marketing Disguised as Science Embarrasses Everyone Involved
A prominent medical journal embarrrasses itself by publishing a flawed study from the American Board of Internal Medicine. Critical appraisal lessons are obvious.
Randomized Trials Should Determine Causality and Be Useful in the Clinic—But Sometimes Accomplish Neither
The recent RCT comparing lactated ringers vs normal saline fails to answer the decades-old question. Here is why.
Aspiration Thrombectomy for Coronary Stent Thrombosis | NEJM
A 73-year-old woman presented with severe chest pain. She had undergone multivessel percutaneous coronary intervention 2.5 years earlier. Angiography revealed a large thrombus in an…
Management of Tricuspid Regurgitation—What’s Next?
This Viewpoint discusses the need to better define whom to treat, when to intervene, how and why to perform an intervention, and what benefit to…
Aspiration Thrombectomy for Coronary Stent Thrombosis | NEJM
A 73-year-old woman presented with severe chest pain. She had undergone multivessel percutaneous coronary intervention 2.5 years earlier. Angiography revealed a large thrombus in an…
Aspiration Thrombectomy for Coronary Stent Thrombosis | NEJM
A 73-year-old woman presented with severe chest pain. She had undergone multivessel percutaneous coronary intervention 2.5 years earlier. Angiography revealed a large thrombus in an…
Exercise is Great but It’s Not a Cancer Drug
The CHALLENGE trial ignited social media with its great story of exercise as a cancer therapeutic. But liking a conclusion is not a reason to…